DUBLIN — April 2, 2020 — Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it has acquired Curzion Pharmaceuticals, Inc., a privately held development-stage biopharma company, and its development-stage oral...
Pappas Ventures closes on fourth fund
News | 03. 10. 2009
RESEARCH TRIANGLE PARK, N.C., March 10, 2009 — Pappas Ventures today announced the final closing of its fourth fund, a $102 million venture capital fund focused on the life sciences sector. Like its immediate predecessor funds, Pappas Ventures IV will invest in product-oriented biopharmaceutical companies, with a secondary focus on medical technologies.
